PharmaShots Interview: Trialbee’s Matt Walz Shares Insight on Trialbee Honey Platform

In an interview with PharmaShots, Matt Walz, CEO at Trialbee share his views on the launch of the Trialbee Honey platform to empower patient recruitment

Shots:

Trialbee launched Trialbee Honey that allows to track, measure, and analyze all patient enrollment activities in clinical trials
The platform is designed to address clinical research and trial barriers by using data to optimize the patient experience, reduce site burden, and empower sponsors and CROs
Trialbee HIVE is a patient-recruitment solution that uses the power of data science to deliver high-quality, study-ready patients. Additionally, Trialbee’s eConsent focuses on patient journey and lower burden for sites and sponsors by digitizing the consent process

Tuba: Can we talk a little about Trialbee as a company?
Matt Walz: Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Partnering with sponsors, CROs, and virtual/decentralized sites, and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. Trialbee Hive operationalizes real-world data (RWD) and applies data science to match patients globally. Trialbee Honey simplifies the journey for matched patients, reduces the burden of enrolling patients for sites, and provides real-time, data-driven insights to sponsors and CROs so they can optimize enrollment timelines.

Tuba: How does Trialbee ease the patient journey during a trial process?
Matt Walz: Easing the patient’s journey can be accomplished by providing a single place online for patients to get the information they need. By directing all recruitment messaging toward a single landing page, we can allow patients to self-screen quickly, build in triggers that clearly guide patients through each step in the process, and enable fast movement from self-screen to nurse assessment and onto enrollment.

To simplify the patient journey, Trialbee works with clients to employ its proprietary and data-driven recruitment strategies. Using complex algorithms and data-mining approaches, we can get clear study messaging to the right patients, in the right places, at the right times. This brings candidates who are likely to be eligible for the study into the landing page where the simplified funnel process gets them screened and enrolled without adding undue burden.

Easing patient burden during recruitment can make a significant difference in getting the required number of eligible candidates into a study while meeting timelines.

Tuba: Can you shed some light individually on Trialbee Hive, Trialbee Honey, and eConsent?
Matt Walz: Trialbee HIVE is a patient-recruitment solution that harnesses the power of data science to deliver high-quality, study-ready patients. It aggregates disparate data silos, employs advanced data science techniques such as look-alike modeling, and scales reach by targeting the optimal channels for your clinical study. This allows sponsors and CROs to identify and match the largest group of the most motivated patients for their clinical trials by leveraging real-world data that is tailored to the clinical trial’s unique needs with the most advanced recruitment strategies.

Trialbee Honey, another patient recruitment platform, was purpose-built to provide transparency into patient qualification and enable convenient patient communication and engagement, making it an efficient solution for sites to engage highly qualified patients. Honey manages enrollment of all patients, regardless of the recruitment source, in a single, purpose-built solution. The robust analytics dashboard enables participants recruited from multiple sources to be consolidated and for efficiencies to be gained by leveraging real-time analytics and full transparency into the funnel. Successful implementation of a recruitment strategy powered by Trialbee Honey can result in improved recruitment timelines, a better experience for patients, streamlined recruitment processes, better candidate diversity, and higher-performing sites.

Finally, Trialbee’s eConsent aims to ease the patient journey and lower the burden for sites and sponsors by digitizing the consent process.

Tuba: Aside from recruitment and eConsent, what areas within clinical research does Trialbee look to optimize for CROs, the Pharma industry, and patients?
Matt Walz: Recent years have seen a seismic shift in the use of new technologies to facilitate clinical trials. The majority of these technologies, particularly those commonly used in decentralized clinical trials (DCTs), help by enabling better patient experiences. These approaches are helping sponsors to open access to research for larger and broader groups of candidates and can be of great help in keeping patients engaged over the course of a study. Trialbee has recognized applying a patient-first way of thinking to the recruitment phase, specifically, is similarly beneficial.

The speed at which sponsors are learning about their candidates is also helpful in terms of trial site optimization. Sites will be seeing the candidates funneling in and will respond accordingly to begin the eligibility vetting process. Trialbee Honey shows sponsors which sites are the most efficient in their follow-up – which ones are best at getting eligible candidates enrolled quickly. With this information, sponsors can focus recruitment efforts to guide more patients toward these high-performing sites, while identifying strategies to improve lower-performance sites.

Access to data regarding where candidates are coming from holds the potential to help sponsors finally make real strides in increasing the population diversity of enrollees. Once sponsors see which recruitment campaigns are resonating with certain demographics of patients, they can allocate a budget toward those channels that are able to deliver the most representative group of study participants.

Tuba: How do you make sure patient data is secure? Are you HIPAA compliant?
Matt Walz: Trialbee adheres to HIPAA and GDPR compliance and our policies and procedures address relevant data security controls. Trialbee's cloud infrastructure resides in Amazon Web Services and is SOC2, Type II compliant, with certifications for ISO/IEC 27001 and CSA Star CCM.

Source: Outsourcing Pharma

About Author: Matt Walz is the CEO of Trialbee. He has more than 20 years of software and leadership experience in the life sciences industry. Mr. Walz received a BS Degree in Computer Science and an MBA, both from the University of Delaware